Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Wang, Xun; Zhao, Xiaoyu; Song, Jieyu; Wu, Jing; Zhu, Yuqi; Li, Minghui; Cui, Yuchen; Chen, Yanjia; Yang, Lulu; Liu, Jun; Zhu, Huanzhang; Jiang, Shibo; Wang, Pengfei
• Is Part Of: Emerging microbes & infections. Volume 11:Issue 1(2022)
• Page Start: 477
• Page End: 481
• Publication Date: 2022-12-31
• Subjects: SARS-CoV-2 -- Omicron -- convalescent -- inactivated vaccine -- monoclonal antibodies; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1080/22221751.2022.2030200
• Languages: English
• ISSNs: 2222-1751

Abstract

ABSTRACT: The massive and rapid transmission of SARS-CoV-2 has led to the emergence of several viral variants of concern (VOCs), with the most recent one, B.1.1.529 (Omicron), which accumulated a large number of spike mutations, raising the specter that this newly identified variant may escape from the currently available vaccines and therapeutic antibodies. Using VSV-based pseudovirus, we found that Omicron variant is markedly resistant to neutralization of sera from convalescents or individuals vaccinated by two doses of inactivated whole-virion vaccines (BBIBP-CorV). However, a homologous inactivated vaccine booster or a heterologous booster with protein subunit vaccine (ZF2001) significantly increased neutralization titers to both WT and Omicron variant. Moreover, at day 14 post the third dose, neutralizing antibody titer reduction for Omicron was less than that for convalescents or individuals who had only two doses of the vaccine, indicating that a homologous or heterologous booster can reduce the Omicron escape from neutralizing. In addition, we tested a panel of 17 SARS-CoV-2 monoclonal antibodies (mAbs). Omicron resists seven of eight authorized/approved mAbs, as well as most of the other mAbs targeting distinct epitopes on RBD and NTD. Taken together, our results suggest the urgency to push forward the booster vaccination to combat the emerging SARS-CoV-2 variants.